Proactive Investors - Run By Investors For Investors

Verona Pharma's chief medical officer to quit at the end of the month

The search is already underway for Kenneth Newman's replacement
doctor looking at lung x-ray
The company is developing a drug for chronic obstructive pulmonary disease

Respiratory specialist Verona Pharma PLC (LON:VRP, NASDAQ:VRNA) said its chief medical officer, Kenneth Newman, is quitting the company at the end of the month to “pursue other opportunities”.

The search is already underway for his replacement.

WATCH: Can Verona Pharma hit the dizzy heights of 5p again?

Chief executive Jan-Anders Karlsson thanked Newman for his “outstanding service” over the past three years.

This included the acceleration into phase IIb clinical trials of Verona’s chronic obstructive pulmonary disease drug candidate.

In total, Newman oversaw seven clinical trials and played an instrumental role in establishing the drug developer’s US presence.

View full VRP profile View Profile

Verona Pharma Timeline

June 20 2016
November 26 2010

Related Articles

February 27 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies
dna strand
May 08 2019
The latest update reveals the company significant clinical and commercial milestones in sight
picture of a knee
May 20 2019
We take a closer look at Collagen Solutions, which received third-party validation of its business model in the form of outside investment from a blue-chip US agriculture company
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use